← Leaderboards
Christopher Kane Breuer
Research Inst Nationwide Children'S Hosp
$17,456,519
Attributed
$23,367,250
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,367,250 · 12
By mechanism
R01$19,298,005 · 6
UH3$2,061,658 · 1
K08$665,550 · 1
UG3$585,096 · 1
R41$448,045 · 2
R43$308,896 · 1
Top collaborators
- Jay D Humphrey13 shared
- Alison L Marsden8 shared
- Yadong Wang5 shared
- Cameron Austin Best1 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Cameron Austin Best$166,777
- Mackenzie Turner$44,667
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignOperative Surgical ProceduresVascular GraftBlood VesselsScaffoldClinical TrialsChildTissue EngineeringGrowthMorbidity - Disease RateImplantCause Of DeathStenosisCongenital AbnormalityVascular Tissue EngineeringImproved OutcomeNewborn InfantMortalityCellsSafetyPreventCardiac Surgery ProceduresMedicalAutologous
Grant awards (55)
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$666,476
R01 · FY2025 · HL · contact PI
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts$300,539
R01 · FY2025 · HL · contact PI
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$666,199
R01 · FY2024 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$628,730
R01 · FY2024 · HL · contact PI
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)$593,214
UH3 · FY2024 · HL · contact PI
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts$294,528
R01 · FY2024 · HL · contact PI
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts$81,825
R01 · FY2024 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$77,902
R01 · FY2024 · HL · contact PI
A preclinical study evaluating and comparing the efficacy of tissue engineered vascular grafts to polytetrafluoroethylene grafts - DIVERSITY SUPP VILLARREAL$51,566
R01 · FY2024 · HL · contact PI
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$692,237
R01 · FY2023 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$641,562
R01 · FY2023 · HL · contact PI
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts$306,779
R01 · FY2023 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$77,349
R01 · FY2023 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$11,391
R01 · FY2023 · HL · contact PI
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$731,320
R01 · FY2022 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$668,604
R01 · FY2022 · HL · contact PI
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)$552,909
UH3 · FY2022 · HL · contact PI
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)$375,901
UH3 · FY2022 · HL · contact PI
A Preclinical Study Evaluating and Comparing the Efficacy of Tissue Engineered Vascular Grafts to Polytetrafluoroethylene Grafts$335,054
R01 · FY2022 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$70,925
R01 · FY2022 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$9,861
R01 · FY2022 · HL · contact PI
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$882,339
R01 · FY2021 · HL · contact PI
Elucidating the Molecular Mechanisms Underlying LYST-mediated Tissue Engineered Vascular Graft Stenosis$675,584
R01 · FY2021 · HL · contact PI
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)$539,634
UH3 · FY2021 · HL · contact PI
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$928,842
R01 · FY2020 · HL · contact PI
Development of a LystaMab coated pericardial adhesion barrier$308,896
R43 · FY2020 · HL
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$964,560
R01 · FY2019 · HL · contact PI
Development of an Improved Vascular Graft for Use in Congenital Heart Surgery$695,806
R01 · FY2019 · HL · contact PI
A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)$585,096
UG3 · FY2019 · HL · contact PI
LystaMab Immunotherapy to Inhibit Pericardial Adhesions$225,342
R41 · FY2019 · HL · contact PI
Improving Tissue Engineered Vascular Graft Performance via Computational Modeling$917,170
R01 · FY2018 · HL · contact PI
Development of an Improved Vascular Graft for Use in Congenital Heart Surgery$707,537
R01 · FY2018 · HL · contact PI
Computational Model Driven Design of Tissue Engineered Vascular Grafts$497,884
R01 · FY2018 · HL
Mechanisms of Vascular Neotissue Formation in Tissue Engineered Vascular Grafts$374,633
R01 · FY2018 · HL · contact PI
Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance$222,703
R41 · FY2018 · HL · contact PI
Development of an Improved Vascular Graft for Use in Congenital Heart Surgery$708,751
R01 · FY2017 · HL · contact PI
Computational Model Driven Design of Tissue Engineered Vascular Grafts$575,141
R01 · FY2017 · HL
Mechanisms of Vascular Neotissue Formation in Tissue Engineered Vascular Grafts$428,533
R01 · FY2017 · HL · contact PI
Development of an Improved Vascular Graft for Use in Congenital Heart Surgery$721,251
R01 · FY2016 · HL · contact PI
Computational Model Driven Design of Tissue Engineered Vascular Grafts$494,739
R01 · FY2016 · HL
Mechanisms of Vascular Neotissue Formation in Tissue Engineered Vascular Grafts$460,966
R01 · FY2016 · HL · contact PI
Computational Model Driven Design of Tissue Engineered Vascular Grafts$84,989
R01 · FY2016 · HL
Mechanisms of Vascular Neotissue Formation in Tissue Engineered Vascular Grafts$53,698
R01 · FY2016 · HL · contact PI
Computational Model Driven Design of Tissue Engineered Vascular Grafts$532,529
R01 · FY2015 · HL
Mechanisms of Vascular Neotissue Formation in Tissue Engineered Vascular Grafts$387,133
R01 · FY2015 · HL · contact PI
Mechanisms of Vascular Neotissue Formation In Tissue Engineered Vascular Grafts$326,562
R01 · FY2014 · HL · contact PI
Mechanisms of Vascular Neotissue Formation In Tissue Engineered Vascular Grafts$329,398
R01 · FY2013 · HL · contact PI
Mechanisms of Vascular Neotissue Formation In Tissue Engineered Vascular Grafts$409,613
R01 · FY2012 · HL · contact PI
Investigating the Mechanisms of Vascular Neotissue Formation In Tissue Engineered$413,750
R01 · FY2011 · HL · contact PI
Investigating the Mechanisms of Vascular Neotissue Formation In Tissue Engineered$413,750
R01 · FY2010 · HL · contact PI
Development of Second Generation Tissue Engineered Vascular Grafts$133,110
K08 · FY2010 · HL · contact PI
Development of Second Generation Tissue Engineered Vascular Grafts$133,110
K08 · FY2009 · HL · contact PI
Development of Second Generation Tissue Engineered Vascular Grafts$133,110
K08 · FY2008 · HL · contact PI
Development of Second Generation Tissue Engineered Vascular Grafts$133,110
K08 · FY2007 · HL · contact PI
Development of Second Generation Tissue Engineered Vascular Grafts$133,110
K08 · FY2006 · HL · contact PI